Glenmark to sell US firms' products in US

Bs_logoImage
Our Corporate Bureau Mumbai
Last Updated : Jun 14 2013 | 3:43 PM IST
In an unusual development, an Indian company will start selling products of two US companies in their home market.
 
Glenmark Pharmaceuticals today announced its alliance with two US-based companies "" Interpharm and Konec "" for marketing their generic products Naproxen and Nitroglycerin in the US with immediate effect.
 
Glenmark expects to further add 4-5 products in its portfolio through a mix of similar alliances, product buyouts and launch of its own products.
 
"This is our US entry strategy. The idea is to accelerate our strategically positioned commercial sales front in the US market. We expect the US business to contribute 25 per cent to our total turnover in three years," Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, said.
 
The company is also assessing other development and marketing alliances on a global basis with several other companies.
 
As per the agreement, the two American companies will continue to manufacture the product. The deal will be executed through Glenmark's US subsidiary "" Glenmark Inc "" which expects to generate sales worth $6-8 million from the two products in the first year, while $1 million sales during the first quarter of the launch.
 
The market for the pain medication drug Naproxen and cardiovascular drug Nitrogycerin in the US is around $80 million and $17 million, respectively.
 
While Nitroglycerin will be marketed under the Glenmark label, Naproxen will be marketed under a joint label with Interpharm Inc.
 
"The in-licensing of these products complement Glenmark's organic product pipeline. Post addition of another 4-5 products under our own label by 2006, we would we are expecting business in excess of $ 10 million," said Terry Coughlin, president of Glenmark Pharmaceuticals Inc.

 
 

Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories

  • Over 30 subscriber-only stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 11 2005 | 12:00 AM IST